| Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of … A Sartore-Bianchi, L Trusolino, C Martino, K Bencardino, S Lonardi, ... The Lancet Oncology 17 (6), 738-746, 2016 | 949 | 2016 |
| Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor … F Ciardiello, R Caputo, V Damiano, R Caputo, T Troiani, D Vitagliano, ... Clinical Cancer Research 9 (4), 1546-1556, 2003 | 459 | 2003 |
| Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth … F Ciardiello, R Bianco, R Caputo, R Caputo, V Damiano, T Troiani, ... Clinical Cancer Research 10 (2), 784-793, 2004 | 421 | 2004 |
| ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research C Marchiò, M Scaltriti, M Ladanyi, AJ Iafrate, F Bibeau, M Dietel, ... Annals of Oncology 30 (9), 1417-1427, 2019 | 354 | 2019 |
| Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa) C Bianco, G Tortora, R Bianco, R Caputo, BM Veneziani, R Caputo, ... Clinical cancer research 8 (10), 3250-3258, 2002 | 337 | 2002 |
| Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy D Ciardiello, PP Vitiello, C Cardone, G Martini, T Troiani, E Martinelli, ... Cancer treatment reviews 76, 22-32, 2019 | 258 | 2019 |
| Global cancer control: responding to the growing burden, rising costs and inequalities in access GW Prager, S Braga, B Bystricky, C Qvortrup, C Criscitiello, E Esin, ... ESMO open 3 (2), e000285, 2018 | 241 | 2018 |
| Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer G Galizia, E Lieto, F De Vita, M Orditura, P Castellano, T Troiani, ... Oncogene 26 (25), 3654-3660, 2007 | 202 | 2007 |
| Erlotinib in cancer treatment MA Bareschino, C Schettino, T Troiani, E Martinelli, F Morgillo, ... Annals of oncology 18, vi35-vi41, 2007 | 182 | 2007 |
| Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors MP Morelli, T Cascone, T Troiani, F De Vita, M Orditura, G Laus, ... Annals of Oncology 16, iv61-iv68, 2005 | 159 | 2005 |
| Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR–MET interaction and activation of MET signaling in colon cancer cells T Troiani, E Martinelli, S Napolitano, D Vitagliano, LP Ciuffreda, ... Clinical cancer research 19 (24), 6751-6765, 2013 | 157 | 2013 |
| Targeting EGFR in pancreatic cancer treatment T Troiani, E Martinelli, A Capasso, F Morgillo, M Orditura, F De Vita, ... Current drug targets 13 (6), 802-810, 2012 | 153 | 2012 |
| Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives E Martinelli, D Ciardiello, G Martini, T Troiani, C Cardone, PP Vitiello, ... Annals of Oncology 31 (1), 30-40, 2020 | 146 | 2020 |
| Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK E Martinelli, F Morgillo, T Troiani, F Ciardiello Cancer treatment reviews 53, 61-69, 2017 | 146 | 2017 |
| Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy F Ciardiello, T Troiani, R Bianco, M Orditura, F Morgillo, E Martinelli, ... Annals of Oncology 17, vii109-vii114, 2006 | 142 | 2006 |
| Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines F Morgillo, FC Sasso, CM Della Corte, D Vitagliano, E D'Aiuto, T Troiani, ... Clinical Cancer Research 19 (13), 3508-3519, 2013 | 137 | 2013 |
| Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial N Normanno, AM Rachiglio, M Lambiase, E Martinelli, F Fenizia, ... Annals of oncology 26 (8), 1710-1714, 2015 | 135 | 2015 |
| Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy R Bianco, T Troiani, G Tortora, F Ciardiello Endocrine-related cancer 12 (Supplement_1), S159-S171, 2005 | 135 | 2005 |
| Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial F Ciardiello, N Normanno, E Maiello, E Martinelli, T Troiani, S Pisconti, ... Annals of oncology 25 (9), 1756-1761, 2014 | 133 | 2014 |
| Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer V Sforza, E Martinelli, F Ciardiello, V Gambardella, S Napolitano, ... World journal of gastroenterology 22 (28), 6345, 2016 | 126 | 2016 |
